Definium Therapeutics to Participate at Upcoming Investor Conferences

Definium Therapeutics Inc. (DFTX) — NEW YORK, November 03, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences:

Source: Business Wire — read the full announcement there.

Browse more sector announcements in our press release archive.